Skip to main content
. Author manuscript; available in PMC: 2020 Sep 28.
Published in final edited form as: J Invest Dermatol. 2019 Aug 26;140(3):713–716. doi: 10.1016/j.jid.2019.07.714

Figure 2. Inhibition of SATB1 promotes expression of IL-5 and IL-9.

Figure 2.

The malignant SS cell line SeAx was treated with (a) siRNA against SATB1 or non-target control or (b) antagomir-155 or antagomir control. RNA was purified 48 hours after treatment, and gene expression was analyzed by qPCR with GAPDH as control. Results are shown as relative values to expression in non-target controls arbitrarily defined as 1. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; qPCR, quantitative reverse transcriptase in real time; SATB1, special AT-rich sequence-binding protein-1; SS, Sézary syndrome; siRNA, small interfering RNA.